Hematological Malignancies

Nivolumab in clinical trials All B-Cell Lymphoma Patient Responses

* ** *

100 110 120

Diffuse Large B-Cell lymphoma Follicular B-Cell Lymphoma Other B-Cell Lymphoma Upper Limit Approximately 540% Upper Limit Approximately 238% * ** Upper Limit Approximately 615%

10 20 30 40 50 60 70 80 90

-30 -20 -10 0

-40 -50 -60 -70 -80 -90 -100

Percent Change from Baseline

0

8

16

24

32

40

48

56

64

72

80

88

96

Time since first dose (weeks)

Moskowitz C, ASH 2014